Codexis Inc (CDXS) Operating Margin

Codexis Bio (CDXS) - corporate logo

Codexis, Inc. (CDXS) leads in enzyme development, advancing ECO Synthesis for RNA therapeutics and green chemistry. The operating margin spread confirms the effectiveness of this strategy, where the indicator value reaches -14.40. The business relies on the sale of consumables and licenses, generating stable FCF. Stability is ensured by a strong staff of protein engineers retained through equity options.

CDXS - Codexis Bio Return on Sales by Operating Profit over the range 07/04/2022 - 11/19/2026

Analytical breakdowns for Codexis Bio (CDXS)

- share price and consensus valuation forecast:
- market capitalization details:
General company analysis:codexis.com, CDXS
Finished products of Codexis Inc

Leveraging the CodeEvolver platform and inelastic demand for catalysts, Codexis, Inc. (CDXS) effectively monetizes its technological uniqueness. This operating margin quantifies the efficiency of converting revenue into earnings before interest and taxes. The metric measures the internal efficiency of the business model, excluding the impact of financial leverage. Growth in this indicator confirms the issuer's pricing power. Analyzing the operating margin helps avoid overpaying at local extremes.

Main competitors

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin PRQR (ProQR)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability